Treating The Three Major Hurdles Of Overcoming Alcohol Use Disorder (AUD)
At AddGraft Therapeutics we have developed a therapeutic platform that, through a onetime and first of its kind treatment, will effectively cure someone of alcohol use disorder (AUD). Our treatment is long lasting, highly effective, and minimally invasive.
This is completed through utilizing skin epidermal progenitor cells to deliver one or more therapeutic agents. First, we harvest skin stem cells from a AUD patient and genetically modify them using a precise molecular scissor CRISPR. This process will introduce genes that can produce molecules which will significantly reduce the motivation to take or seek alcohol. Then, we reimplant these skin cells into the original host through a skin graft. After the graft has been reimplanted, the skin graft is able to produce these molecules as a bio engine throughout the lifetime of the graft.
We are currently in the pre-clinical stage of our technology development and are preparing to transition this work into human clinical trials within the next few years.
CEO and Co Founder
Ryan is a former healthcare management consultant who has spent his career leading healthcare organizations through mergers, acquisitions, and reorgs. Additionally, Ryan has worked in venture and understands the process of raising and managing investment.
He has significant experience in project management, P&L evaluation and strategic decision making. Ryan is also currently completing his MBA at the Booth School of Business at the University of Chicago.
DR. MING XU
CSO and Co Founder
Dr. Ming Xu is world class addiction specialist in addiction. Dr. Xu is a professor of neurobiology in the Biological Science Division at the University of Chicago. Over the last 25 years Dr. Xu’s laboratory has worked to understand mechanisms of drug addiction and worked to find possible treatment strategies.
His laboratory has made significant contributions in advancing knowledge as to how drug addiction occurs and how we might treat this complex brain disease.
DR. XIAOYANG WU
CTO and Co Founder
Dr. Xiaoyang Wu is an associate professor of tissue engineering in the Biological Science Division at the University of Chicago. Dr. Wu’s long-term interest is to explore cell signaling and the molecular mechanisms controlling somatic stem cell behavior and somatic gene therapy.
His laboratory has significantly advanced our understanding of how skin injuries activate quiescent epidermal stem cells to proliferate and migrate to repair a wound.